Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesXenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
XenoPort, 07/01/09
XenoPort, Inc. announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil, also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury. Doses of 20 and 30 mg of AP, given twice daily, demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases
Current Medical Research and Opinion, 12/18/09
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 12/18/09
Iron supplementation in the non-dialysis chronic kidney disease patient: oral or intravenous
Current Medical Research and Opinion, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor